Innovation Hub
/
Blog
/
All Recombinant Proteins Are Not the Same: From Antigens to Avi-tags

All Recombinant Proteins Are Not the Same: From Antigens to Avi-tags

Date: August 12, 2020. Time: 11:00 AM EST. In mid-August, the Bio-Techne team shared their vast industry expertise in a webinar focusing on...

Scientist.com

Date: August 12, 2020. Time: 11:00 AM EST.

In mid-August, the Bio-Techne team shared their vast industry expertise in a webinar focusing on recombinant protein selection, customization and application. The featured panelists — Bio-Techne’s Martin Ramsden, Director Commercial Development and John Humphrey, Director Molecular and Cellular Biology — presented on recombinant protein applications, specifically biotinylated proteins, including site-specific Avi-tag biotinylation. Humphrey also spoke at length about COVID-19 SARS proteins available through Bio-Techne.

Watch Video

Abstract molecular cluster with three connected blue-green spheres on a white background.

Take the Next Step

Explore Suppliers

Browse trusted partners with relevant expertise

Review Capabilities

Compare services, experience, and past work

Start Your Project

Connect and begin collaborating

Browse Suppliers

Post a Project

How It Works

Written by

Scientist.com

Share this post

TOPICS

Protein Sciences

Antibodies

Subscribe to our newsletter

Subscribe to receive the latest news and innovations straight to your inbox.

Your subscription could not be saved. Please try again.

Your subscription has been successful.

Topics of Interest

Biology
Biometrics
Chemical & Compound Analysis
Chemistry, Manufacturing & Controls
Clinical Trials
Discovery Chemistry
DMPK
Health Economics & Outcomes Research (HEOR)
Human Biological Samples (HBS)
Market Access
Non-Human Biological Samples (NHBS)
Pharmacology
Raw Materials
Real-World Data (RWD)
Real-World Evidence (RWE)
Safety & Pharmacovigilance
Toxicology
Medical Communications

Email address

I would like to receive the monthly Scientist.com newsletter.

I agree to receive email communication from Scientist.com and accept the data privacy statement.

By submitting your information, you agree to our Terms of Service and Privacy Policy. You can opt out anytime.

Subscribe to our newsletter

Subscribe to receive the latest news and innovations straight to your inbox.

Your subscription could not be saved. Please try again.

Your subscription has been successful.

Topics of Interest

Biology
Biometrics
Chemical & Compound Analysis
Chemistry, Manufacturing & Controls
Clinical Trials
Discovery Chemistry
DMPK
Health Economics & Outcomes Research (HEOR)
Human Biological Samples (HBS)
Market Access
Non-Human Biological Samples (NHBS)
Pharmacology
Raw Materials
Real-World Data (RWD)
Real-World Evidence (RWE)
Safety & Pharmacovigilance
Toxicology
Medical Communications

Email address

I would like to receive the monthly Scientist.com newsletter.

I agree to receive email communication from Scientist.com and accept the data privacy statement.

By submitting your information, you agree to our Terms of Service and Privacy Policy. You can opt out anytime.

Read Further

Blog

Ignyte Bio's Antigen-Specific T cells in NAM

Innovation Hub

All Recombinant Proteins Are Not the Same: From Antigens to Avi-tags

Take the Next Step

Explore Suppliers

Review Capabilities

Start Your Project

Subscribe to our newsletter

Subscribe to our newsletter

Read Further

Ignyte Bio's Antigen-Specific T cells in NAM

What AI Finds in Clinical Notes About Myasthenia Gravis That Claims Data Misses

In Vivo Study: From Study Design, Execution to Pathology Assessment in One Laboratory at APS

The AI-Native Drug Discovery Program of the Future

From San Diego to Switzerland: Revisiting Scientist.com’s Vendor Discovery Days in 2026

What to Know About AAV Quality Before the Experiment Begins

Immortalized vs. Primary Cells: Choosing the Right Model for Your Research

AI Isn’t Replacing the Scientific Method. It’s Accelerating It.

Connecting Discovery: How Integrated Infrastructure Supports Better Decisions

What Experimental Data Do AI-Designed Antibodies Need?

From Vague Claims to Strict Compliance: The Global Regulatory Crackdown on Greenwashing

The Evolving Landscape of Drug Discovery for Metabolic Diseases

Regulatory Evolution in Substantial Evidence: The FDA’s One-Trial Pathway and the Strategic Implications for Biopharmaceutical Development

June 2026 Medical/Commercial Pulse Check

Accelerating the Design–Build–Test–Learn Cycle for AI-Driven Antibody Discovery

Screening the Unscreenable: How Physics-Grounded AI Is Expanding the Reach of Drug Discovery

Reducing risk in CRO studies: Choosing the right cell models for outsourced research

Cutting Months Off AAV Programs: The Synthetic DNA Shift

Speed Matters: Why RWE Acceleration Starts Upstream with Reusable Data

Industry Insights: Behind the Scenes of BPS Bioscience Custom R&D

Making Sustainability More "Sustainable": Driving Transformation at Scale within Biopharma

Comprehensive Plasma cell-free RNA Profiling for Superior Cancer Detection

Advanced Screening Strategies for Molecular Glue Discovery

Why Large CROs and CDMOs Should Embrace Research Orchestration Platforms - Even with Existing Pharma Clients

AI in HEOR: Three Ways Artificial Intelligence Is Accelerating Evidence Generation

Supplier Spotlight: RadMD Imaging

AI Is Expanding What's Possible in Drug Discovery. Operational Friction Still Determines How Fast It Happens.

The Science of the "Gut Feeling": Why Techs are a Lab's Best Diagnostic Tool

Supplier Spotlight: MedChemExpress

HealthEconomics.com 2026 Pulse Check – March

Read Further

Ignyte Bio's Antigen-Specific T cells in NAM

In Vivo Study: From Study Design, Execution to Pathology Assessment in One Laboratory at APS

What AI Finds in Clinical Notes About Myasthenia Gravis That Claims Data Misses

The AI-Native Drug Discovery Program of the Future

The Digital Backbone for Modern Life Sciences